[
  {
    "ts": "2025-11-28T09:21:45+00:00",
    "headline": "Is Bristol-Myers Stock Underperforming the S&P 500?",
    "summary": "Bristol-Myers has lagged behind the broader S&P 500 Index, and Wall Street remains cautious about this stock.",
    "url": "https://www.barchart.com/story/news/36354017/is-bristol-myers-stock-underperforming-the-s-p-500",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "2610d650-67eb-3763-8650-c9a2f618df32",
      "content": {
        "id": "2610d650-67eb-3763-8650-c9a2f618df32",
        "contentType": "STORY",
        "title": "Is Bristol-Myers Stock Underperforming the S&P 500?",
        "description": "",
        "summary": "Bristol-Myers has lagged behind the broader S&P 500 Index, and Wall Street remains cautious about this stock.",
        "pubDate": "2025-11-28T09:21:45Z",
        "displayTime": "2025-11-28T09:21:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/274574e1087b6c22ee87eee0dcb266a8",
          "originalWidth": 887,
          "originalHeight": 1183,
          "caption": "Bristol-Myers Squibb Co_ logo on building-by tatu Campelo via iStock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X66tq9zV8vSDHQnc_5N4fw--~B/aD0xMTgzO3c9ODg3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/274574e1087b6c22ee87eee0dcb266a8.cf.webp",
              "width": 887,
              "height": 1183,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iHZBJXJb5FaJ7jG3vePFMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/274574e1087b6c22ee87eee0dcb266a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36354017/is-bristol-myers-stock-underperforming-the-s-p-500",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-stock-underperforming-p-092145192.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-28T14:10:30+00:00",
    "headline": "Bristol-Myers Squibb Surges 15% After Drug Approvals: Is the Stock a Bargain in 2025?",
    "summary": "Wondering if Bristol-Myers Squibb is a bargain or overpriced? Let’s dig into what’s behind the numbers so you can decide with confidence. After a rocky start to the year, Bristol-Myers Squibb has staged an impressive rebound, gaining 15.6% in the last month and 6.5% in just the past week. However, it is still down 13.3% year-to-date. Investor sentiment has been shaped by headlines ranging from major drug approvals to strategic partnerships, which have fueled recent optimism about...",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-surges-15-141030823.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d4420a9a-b508-38a8-8fbb-3df5e897c211",
      "content": {
        "id": "d4420a9a-b508-38a8-8fbb-3df5e897c211",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb Surges 15% After Drug Approvals: Is the Stock a Bargain in 2025?",
        "description": "",
        "summary": "Wondering if Bristol-Myers Squibb is a bargain or overpriced? Let’s dig into what’s behind the numbers so you can decide with confidence. After a rocky start to the year, Bristol-Myers Squibb has staged an impressive rebound, gaining 15.6% in the last month and 6.5% in just the past week. However, it is still down 13.3% year-to-date. Investor sentiment has been shaped by headlines ranging from major drug approvals to strategic partnerships, which have fueled recent optimism about...",
        "pubDate": "2025-11-28T14:10:30Z",
        "displayTime": "2025-11-28T14:10:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-surges-15-141030823.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-surges-15-141030823.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-28T13:35:00+00:00",
    "headline": "Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?",
    "summary": "GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.",
    "url": "https://finance.yahoo.com/news/bristol-myers-vs-gilead-sciences-133500245.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "49f56c52-825b-3c51-b0f6-bf74ff4afc4c",
      "content": {
        "id": "49f56c52-825b-3c51-b0f6-bf74ff4afc4c",
        "contentType": "STORY",
        "title": "Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?",
        "description": "",
        "summary": "GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.",
        "pubDate": "2025-11-28T13:35:00Z",
        "displayTime": "2025-11-28T13:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NuaC8R_wAbhCY5KPvmp9LA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cLIW4zpH3bXqWfT.Oe9Uew--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-vs-gilead-sciences-133500245.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-vs-gilead-sciences-133500245.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]